Found: 2
Select item for more details and to access through your institution.
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 109, doi. 10.1007/s10637-018-0634-5
- By:
- Publication type:
- Article
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1072, doi. 10.1007/s10637-018-0658-x
- By:
- Publication type:
- Article